JOURNAL ARTICLE
Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
Marcus Maurer, Andrea Schütz, Karsten Weller, Nicole Schoepke, Adriane Peveling-Oberhag, Petra Staubach, Sabine Müller, Thilo Jakob, Martin MetzNo abstract text is available yet for this article.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.